A composite score using quantitative magnetic resonance cholangiopancreatography predicts clinical outcomes in primary sclerosing cholangitis

First validated prognostic model of clinical outcomes in PSC using a novel composite marker derived from quantitative MRCP metrics, bilirubin, and AST. It outperformed the traditional Mayo risk score in predicting transplant-free survival in patients with PSC, suggesting improved risk stratification and potential to improve clinical management.